Abstract
Almost one-third of adults with severe headaches/migraines report using nutraceuticals. Many may seek herb/supplements for their “natural” and “safe” profile, but they have limited FDA oversight and are not always impartially tested. Understanding the terminology and regulatory oversight of non-pharmacologic products can help providers appropriately treat and counsel patients about these options. Few studies have evaluated the benefit of nutraceuticals specifically for chronic daily headache. In this chapter, the research evidence for nutraceuticals for primary headache disorders is described. If not available, the research presented for headache can be extrapolated for consideration in the treatment of chronic daily headache. Several supplements have Level B evidence of efficacy according to the 2012 American Headache Society and the American Academy of Neurology guidelines, including feverfew (studied dose, 50–300 mg bid; 2.08–18.75 tid of MIG-99), riboflavin (studied dose, 400 mg daily), and magnesium (studied dose, 600 mg trimagnesium dicitrate daily). Coenzyme Q10 (studied dose 100 mg tid) was given Level C evidence. Melatonin, vitamin D, and Ginkgo biloba have limited evidence of potential efficacy for headache. Although Level A evidence exists for Petasites (butterbur), it is not currently recommended secondary to potential for liver toxicity. Homeopathic treatments have little evidence to support their use in chronic daily headache. More research is needed to further clarify benefits of supplements for chronic daily headache.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kalra EK. Nutraceutical–definition and introduction. AAPS PharmSci. 2003;5(3):E25.
Office of dietary supplements–Dietary supplement health and education act of 1994 [Internet]. [cited 2017 Apr 26]. Available from: https://ods.od.nih.gov/About/DSHEA_Wording.aspx
Wallace TC. Twenty years of the dietary supplement health and education act–how should dietary supplements be regulated? J Nutr. 2015;145(8):1683–6.
Rajapakse T, Pringsheim T. Nutraceuticals in migraine: a summary of existing guidelines for use. Headache. 2016;56(4):808–16.
US Food and Drug Administration. Label claims for conventional foods and dietary supplements [Internet]. [cited 2017 Jun 13]. Available from: https://www.fda.gov/food/ingredientspackaginglabeling/labelingnutrition/ucm111447.htm.
Dalla Libera D, Colombo B, Pavan G, Comi G. Complementary and alternative medicine (CAM) use in an Italian cohort of pediatric headache patients: the tip of the iceberg. Neurol Sci. 2014;35(Suppl 1):145–8.
US Food and Drug Administration. FDA investigates elevated lead levels linked to ton shen health/life rising dietary supplements [Internet]. [cited 2017 Jun 13]. Available from: https://www.fda.gov/food/recallsoutbreaksemergencies/outbreaks/ucm518288.htm.
The New York Times. New York Attorney General Targets Supplements at Major Retailers [Internet]. [cited 2017 Jun 13]. Available from: https://well.blogs.nytimes.com/2015/02/03/new-york-attorney-general-targets-supplements-at-major-retailers/.
Wells RE, Bertisch SM, Buettner C, Phillips RS, McCarthy EP. Complementary and alternative medicine use among adults with migraines/severe headaches. Headache. 2011;51(7):1087–97.
Toldo I, Rattin M, Perissinotto E, De Carlo D, Bolzonella B, Nosadini M, et al. Survey on treatments for primary headaches in 13 specialized juvenile headache centers: the first multicenter Italian study. Eur J Paediatr Neurol. 2016;21(3):507–21.
Rossi P, Di Lorenzo G, Malpezzi MG, Faroni J, Cesarino F, Di Lorenzo C, et al. Prevalence, pattern and predictors of use of complementary and alternative medicine (CAM) in migraine patients attending a headache clinic in Italy. Cephalalgia. 2005;25(7):493–506.
Tepper SJ. Nutraceutical and other modalities for the treatment of headache. Continuum Minneap Minn. 2015;21(4 Headache):1018–31.
Mauskop A. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the quality standards Subcommittee of the American Academy of neurology and the American headache society. Neurology. 2013;80(9):868.
Pareek A, Suthar M, Rathore GS, Bansal V. Feverfew (Tanacetum parthenium L.): a systematic review. Pharmacogn Rev. 2011;5(9):103–10.
Wider B, Pittler MH, Ernst E. Feverfew for preventing migraine. In: Cochrane database of systematic reviews. Hoboken, N.J: John Wiley & Sons, Ltd; 2015.
Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev. 2004;1:CD002286.
Diener HC, Pfaffenrath V, Schnitker J, Friede M. Henneicke-von Zepelin H-H. Efficacy and safety of 6.25 mg t.I.D. Feverfew CO2-extract (MIG-99) in migraine prevention–a randomized, double-blind, multicentre, placebo-controlled study. Cephalalgia. 2005;25(11):1031–41.
Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. Br Med J Clin Res Ed. 1985;291(6495):569–73.
Murphy JJ, Heptinstall S, Mitchell JR. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet. 1988;2(8604):189–92.
Palevitch D, Earon G, Carasso R. Feverfew (Tanacetum parthenium) as a prophylactic treatment for migraine: a double-blind placebo-controlled study. Phytother Res. 1997;11(7):508–11.
De Weerdt CJ, Bootsma HP, Hendriks H. Herbal medicines in migraine prevention randomized double-blind placebo-controlled crossover trial of a feverfew preparation. Phytomedicine. 1996;3(3):225–30.
Pfaffenrath V, Diener HC, Fischer M, Friede M, Henneicke-von Zepelin HH. Investigators. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis--a double-blind, multicentre, randomized placebo-controlled dose-response study. Cephalalgia. 2002;22(7):523–32.
Cady RK, Goldstein J, Nett R, Mitchell R, Beach ME, Browning R. A double-blind placebo-controlled pilot study of sublingual feverfew and ginger (LipiGesicTM M) in the treatment of migraine. Headache. 2011;51(7):1078–86.
Loder E, Burch R, Rizzoli P. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache. 2012;52(6):930–45.
Pringsheim T, Davenport WJ, Mackie G, Worthington I, Aubé M, Christie SN, et al. Canadian headache society guideline for migraine prophylaxis. Can J Neurol Sci. 2012;39(2 Suppl 2):S1–59.
Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, et al. EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. Eur J Neurol. 2009;16(9):968–81.
Colombo B, Saraceno L, Comi G. Riboflavin and migraine: the bridge over troubled mitochondria. Neurol Sci. 2014;35(1):141–4.
Mauskop A. Nonmedication, alternative, and complementary treatments for migraine. Continuum Minneap Minn. 2012;18(4):796–806.
Smith CB. Riboflavin in migraine. Can Med Assoc J. 1946;54(6):589.
Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology. 1998;50(2):466–70.
Sándor PS, Afra J, Ambrosini A, Schoenen J. Prophylactic treatment of migraine with beta-blockers and riboflavin: differential effects on the intensity dependence of auditory evoked cortical potentials. Headache. 2000;40(1):30–5.
Boehnke C, Reuter U, Flach U, Schuh-Hofer S, Einhäupl KM, Arnold G. High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care Centre. Eur J Neurol. 2004;11(7):475–7.
MacLennan SC, Wade FM, Forrest KML, Ratanayake PD, Fagan E, Antony J. High-dose riboflavin for migraine prophylaxis in children: a double-blind, randomized, placebo-controlled trial. J Child Neurol. 2008;23(11):1300–4.
Bruijn J, Duivenvoorden H, Passchier J, Locher H, Dijkstra N, Arts W-F. Medium-dose riboflavin as a prophylactic agent in children with migraine: a preliminary placebo-controlled, randomised, double-blind, cross-over trial. Cephalalgia. 2010;30(12):1426–34.
Condò M, Posar A, Arbizzani A, Parmeggiani A. Riboflavin prophylaxis in pediatric and adolescent migraine. J Headache Pain. 2009;10(5):361.
Melnikova AM-E, Schäppi MG, Korff C. Riboflavin in cyclic vomiting syndrome: efficacy in three children. Eur J Pediatr. 2016;175(1):131–5.
Rosanoff A, Weaver CM, Rude RK. Suboptimal magnesium status in the United States: are the health consequences underestimated? Nutr Rev. 2012;70(3):153–64.
Mauskop A, Varughese J. Why all migraine patients should be treated with magnesium. J Neural Transm. 2012;119(5):575–9.
Taylor FR. Nutraceuticals and headache: the biological basis. Headache. 2011;51(3):484–501.
Trauninger A, Pfund Z, Koszegi T, Czopf J. Oral magnesium load test in patients with migraine. Headache. 2002;42(2):114–9.
Samaie A, Asghari N, Ghorbani R, Arda J. Blood magnesium levels in migraineurs within and between the headache attacks: a case control study. Pan Afr Med J. 2012;11:46.
Assarzadegan F, Asgarzadeh S, Hatamabadi HR, Shahrami A, Tabatabaey A, Asgarzadeh M. Serum concentration of magnesium as an independent risk factor in migraine attacks: a matched case-control study and review of the literature. Int Clin Psychopharmacol. 2016;31(5):287–92.
Mauskop A, Altura BT, Altura BM. Serum ionized magnesium levels and serum ionized calcium/ionized magnesium ratios in women with menstrual migraine. Headache. 2002;42(4):242–8.
Peikert A, Wilimzig C, Köhne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia. 1996;16(4):257–63.
Chiu H-Y, Yeh T-H, Huang Y-C, Chen P-Y. Effects of intravenous and oral magnesium on reducing migraine: a meta-analysis of randomized controlled trials. Pain Physician. 2016;19(1):E97–112.
Maizels M, Blumenfeld A, Burchette R. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. Headache. 2004;44(9):885–90.
Pfaffenrath V, Wessely P, Meyer C, Isler HR, Evers S, Grotemeyer KH, et al. Magnesium in the prophylaxis of migraine–a double-blind placebo-controlled study. Cephalalgia. 1996;16(6):436–40.
Wang F, Van Den Eeden SK, Ackerson LM, Salk SE, Reince RH, Elin RJ. Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial. Headache. 2003;43(6):601–10.
Grazzi L, Andrasik F, Usai S, Bussone G. Magnesium as a preventive treatment for paediatric episodic tension-type headache: results at 1-year follow-up. Neurol Sci. 2007;28(3):148–50.
Wells RE, Turner DP, Lee M, Bishop L, Strauss L. Managing migraine during pregnancy and lactation. Curr Neurol Neurosci Rep. 2016;16(4):40.
Markley HG. CoEnzyme Q10 and riboflavin: the mitochondrial connection. Headache. 2012;52(Suppl 2):81–7.
Hershey AD, Powers SW, Vockell A-LB, Lecates SL, Ellinor PL, Segers A, et al. Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine. Headache. 2007;47(1):73–80.
Parikh S, Saneto R, Falk MJ, Anselm I, Cohen BH, Haas R. A modern approach to the treatment of mitochondrial disease. Curr Treat Options Neurol. 2009;11(6):414–30.
Orr SL. Diet and nutraceutical interventions for headache management: a review of the evidence. Cephalalgia. 2016;36(12):1112–33.
Littarru GP, Tiano L. Clinical aspects of coenzyme Q10: an update. Nutr Burbank Los Angel Cty Calif. 2010;26(3):250–4.
Sándor PS, Di Clemente L, Coppola G, Saenger U, Fumal A, Magis D, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology. 2005;64(4):713–5.
Slater SK, Nelson TD, Kabbouche MA, LeCates SL, Horn P, Segers A, et al. A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine. Cephalalgia. 2011;31(8):897–905.
Rozen TD, Oshinsky ML, Gebeline CA, Bradley KC, Young WB, Shechter AL, et al. Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia. 2002;22(2):137–41.
Shoeibi A, Olfati N, Soltani Sabi M, Salehi M, Mali S, Akbari OM. Effectiveness of coenzyme Q10 in prophylactic treatment of migraine headache: an open-label, add-on, controlled trial. Acta Neurol Belg. 2016;117(1):103–9.
Bougea A, Spantideas N, Lyras V, Avramidis T, Thomaidis T. Melatonin 4 mg as prophylactic therapy for primary headaches: a pilot study. Funct Neurol. 2016;31(1):33–7.
Alstadhaug KB, Odeh F, Salvesen R, Bekkelund SI. Prophylaxis of migraine with melatonin: a randomized controlled trial. Neurology. 2010;75(17):1527–32.
Gonçalves AL, Martini Ferreira A, Ribeiro RT, Zukerman E, Cipolla-Neto J, Peres MFP. Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention. J Neurol Neurosurg Psychiatry. 2016;87(10):1127–32.
Rozen TD. How effective is melatonin as a preventive treatment for hemicrania continua? A clinic-based study. Headache. 2015;55(3):430–6.
Rozen TD. Melatonin as treatment for idiopathic stabbing headache. Neurology. 2003;61(6):865–6.
Bandyopadhyay D, Ghosh G, Bandyopadhyay A, Reiter RJ. Melatonin protects against piroxicam-induced gastric ulceration. J Pineal Res. 2004;36(3):195–203.
Leroux E, Ducros A. Cluster headache. Orphanet J Rare Dis. 2008;3:20.
Leone M, Lucini V, D’Amico D, Moschiano F, Maltempo C, Fraschini F, et al. Twenty-four-hour melatonin and cortisol plasma levels in relation to timing of cluster headache. Cephalalgia. 1995;15(3):224–9.
Leone M, D’Amico D, Moschiano F, Fraschini F, Bussone G. Melatonin versus placebo in the prophylaxis of cluster headache: a double-blind pilot study with parallel groups. Cephalalgia. 1996;16(7):494–6.
Pringsheim T, Magnoux E, Dobson CF, Hamel E, Aubé M. Melatonin as adjunctive therapy in the prophylaxis of cluster headache: a pilot study. Headache. 2002;42(8):787–92.
Miano S, Parisi P, Pelliccia A, Luchetti A, Paolino MC, Villa MP. Melatonin to prevent migraine or tension-type headache in children. Neurol Sci. 2008;29(4):285–7.
Bruni O, Alonso-Alconada D, Besag F, Biran V, Braam W, Cortese S, et al. Current role of melatonin in pediatric neurology: clinical recommendations. Eur J Paediatr Neurol. 2015;19(2):122–33.
Pfotenhauer KM, Shubrook JH. Vitamin D deficiency, its role in health and disease, and current supplementation recommendations. J Am Osteopath Assoc. 2017;117(5):301–5.
Buettner C, Burstein R. Association of statin use and risk for severe headache or migraine by serum vitamin D status: a cross-sectional population-based study. Cephalalgia. 2015;35(9):757–66.
Buettner C, Nir R-R, Bertisch SM, Bernstein C, Schain A, Mittleman MA, et al. Simvastatin and vitamin D for migraine prevention: a randomized, controlled trial. Ann Neurol. 2015;78(6):970–81.
Cayir A, Turan MI, Tan H. Effect of vitamin D therapy in addition to amitriptyline on migraine attacks in pediatric patients. Braz J Med Biol Res. 2014;47(4):349–54.
Prakash S, Makwana P, Rathore C. Vitamin D deficiency mimicking chronic tension-type headache in children. BMJ Case Rep. 2016;2016:bcr2015213833.
Kreijkamp-Kaspers S, McGuire T, Bedford S, Loadsman P, Pirotta M, Moses G, et al. Your questions about complementary medicines answered: gingko biloba. Aust Fam Physician. 2015;44(8):565–6.
Allais G, D’Andrea G, Maggio M, Benedetto C. The efficacy of ginkgolide B in the acute treatment of migraine aura: an open preliminary trial. Neurol Sci. 2013;34(Suppl 1):S161–3.
D’Andrea G, Bussone G, Allais G, Aguggia M, D’Onofrio F, Maggio M, et al. Efficacy of Ginkgolide B in the prophylaxis of migraine with aura. Neurol Sci. 2009;30(Suppl 1):S121–4.
Esposito M, Carotenuto M. Ginkgolide B complex efficacy for brief prophylaxis of migraine in school-aged children: an open-label study. Neurol Sci. 2011;32(1):79–81.
Usai S, Grazzi L, Andrasik F, Bussone G. An innovative approach for migraine prevention in young age: a preliminary study. Neurol Sci. 2010;31(Suppl 1):S181–3.
Esposito M, Ruberto M, Pascotto A, Carotenuto M. Nutraceutical preparations in childhood migraine prophylaxis: effects on headache outcomes including disability and behaviour. Neurol Sci. 2012;33(6):1365–8.
Gaul C, Diener H-C, Danesch U. Migravent® study group. Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial. J Headache Pain. 2015;16:516.
Witt CM, Lüdtke R, Willich SN. Homeopathic treatment of patients with migraine: a prospective observational study with a 2-year follow-up period. J Altern Complement Med. 2010;16(4):347–55.
Owen JM, Green BN. Homeopathic treatment of headaches: a systematic review of the literature. J Chiropr Med. 2004;3(2):45–52.
Homeopathy [Internet]. NCCIH. 2012 [cited 2017 Mar 27]. Available from: https://nccih.nih.gov/health/homeopathy.
Wells RE, Baute V, Wahbeh H. Complementary and integrative medicine for neurologic conditions. Med Clin North Am. 2017;101(5):881–9.
Wells RE, Loder E. Mind/body and behavioral treatments: the evidence and approach. Headache. 2012;52(Suppl 2):70–5.
Nahin RL, Barnes PM, Stussman BJ, Bloom B. Costs of complementary and alternative medicine (CAM) and frequency of visits to CAM practitioners: United States, 2007. Natl Health Stat Rep. 2009;18:1–14.
Wells RE, Smitherman TA, Seng EK, Houle TT, Loder EW. Behavioral and mind/body interventions in headache: unanswered questions and future research directions. Headache. 2014;54(6):1107–13.
Przekop P, Przekop A, Haviland MG. Multimodal compared to pharmacologic treatments for chronic tension-type headache in adolescents. J Bodyw Mov Ther. 2016;20(4):715–21.
Cowan RP. CAM in the real world: you may practice evidence-based medicine, but your patients don’t. Headache. 2014;54(6):1097–102.
Tepper SJ. Editorial: complementary and alternative medicine (CAM), Ayurvedic medicine, and research into behavioral and mind/body interventions in headache. Headache. 2014;54(6):1114.
Oinonen SM. Integrative medicine: a necessary component in completing treatment for my chronic migraines. Headache. 2017;57(5):809–11.
Acknowledgments
Dr. Wells is supported by the National Center for Complementary and Integrative Health of the National Institutes of Health under Award Number K23AT008406. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We gratefully acknowledge the editorial assistance of Karen Klein, MA, in the Wake Forest Clinical and Translational Science Institute, funded by the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, through Grant Award Number UL1TR001420. We also thank Mark McKone, Librarian at Carpenter Library, Wake Forest School of Medicine, for his help with the use of Zotero. We are appreciative of the help from Nakiea Choate from the Department of Neurology at Wake Forest Baptist for her administrative support.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Granetzke, L., Paolini, B., Wells, R.E. (2019). Complementary and Alternative Approaches to Chronic Daily Headache: Part III—Nutraceuticals. In: Green, M., Cowan, R., Freitag, F. (eds) Chronic Headache. Springer, Cham. https://doi.org/10.1007/978-3-319-91491-6_20
Download citation
DOI: https://doi.org/10.1007/978-3-319-91491-6_20
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-91490-9
Online ISBN: 978-3-319-91491-6
eBook Packages: MedicineMedicine (R0)